Delta variant in India, a Lancet report said. “Currently, there is a mixed picture on single-dose efficacy of available vaccines against B.1.617.2, the dominant variant now circulating in India.
Early findings from the UK suggest that for ChAdOx1 nCoV-19, single-dose efficacy against this variant is substantially reduced when considering symptomatic infection as an endpoint," said the report. “However, more recent findings suggest that protection against hospitalisation is as high as 71%.
Similarly, single-dose protection against hospitalisation has been reported among healthcare workers in India," it added. It also stated that additional analysis illustrates that rapid-response vaccination could still have a substantial effect on